Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||05/08/2020|
|Rapid review completed||28/09/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of encorafenib plus cetuximab compared with the current standard of care.|